⌘K
Loading ticker…
As of 2026-08-24, Biogen Inc. Common Stock (BIIB) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 57. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 2.9%, relative volume 0.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BIIB is in a stage 2 uptrend, week 5. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 6.1% / 15.8%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
BIIB is held by 81 ETFs as of May 2026. Top owner: VHT at 0.45% weight, $86M notional. Top 3 carry $154M.
Held by 273 ETFs · $5.3B across latest filings · largest weight 5.05% (PBE).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.45% | $86M | +0.04 pp |
| GSLC | 0.23% | $36M | −0.02 pp |
| FNDXSchwab Fundamental U.S. Large Company Index ETF | 0.12% | $31M | −0.02 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.04% | $31M | — |
| VONVVanguard Russell 1000 Value ETF |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.09% |
| $18M |
| — |
| SCHBSchwab U.S. Broad Market ETF | 0.04% | $17M | — |
| ESGU | 0.09% | $16M | −0.03 pp |
| QQQJ | 1.34% | $15M | −0.05 pp |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.09% | $15M | — |
| AVUSAvantis U.S. Equity ETF | 0.06% | $8M | — |
Showing 10 of 81 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BIIB Jan avg: -0.82% median: -1.23% win: 50% σ: 5.30% n: 4 2022-04-12 → 2026-07-31 | BIIB Feb avg: -3.75% median: -4.81% win: 25% σ: 7.96% n: 4 2022-04-12 → 2026-07-31 | BIIB Mar avg: -1.16% median: -1.62% win: 25% σ: 3.19% n: 4 2022-04-12 → 2026-07-31 | BIIB Apr avg: -0.15% median: -0.38% win: 40% σ: 7.65% n: 5 2022-04-12 → 2026-07-31 | BIIB May avg: 1.86% median: 3.55% win: 60% σ: 4.71% n: 5 2022-04-12 → 2026-07-31 | BIIB Jun avg: 1.63% median: 1.97% win: 60% σ: 5.71% n: 5 2022-04-12 → 2026-07-31 | BIIB Jul avg: -2.38% median: -5.15% win: 40% σ: 5.77% n: 5 2022-04-12 → 2026-07-31 | BIIB Aug avg: -2.71% median: -2.50% win: 25% σ: 5.22% n: 4 2022-04-12 → 2026-07-31 (current) | BIIB Sep avg: 8.35% median: 1.04% win: 50% σ: 19.53% n: 4 2022-04-12 → 2026-07-31 | BIIB Oct avg: -0.38% median: -0.71% win: 50% σ: 10.04% n: 4 2022-04-12 → 2026-07-31 | BIIB Nov avg: 4.14% median: 3.10% win: 50% σ: 11.20% n: 4 2022-04-12 → 2026-07-31 | BIIB Dec avg: -1.71% median: -4.08% win: 25% σ: 8.55% n: 4 2022-04-12 → 2026-07-31 |